Syndax Pharmaceuticals, Inc.
SNDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,333 | $809 | $1,052 | $1,134 |
| - Cash | $117 | $109 | $154 | $154 |
| + Debt | $345 | $2 | $346 | $346 |
| Enterprise Value | $1,562 | $702 | $1,244 | $1,326 |
| Revenue | $46 | $38 | $20 | $8 |
| % Growth | 20.8% | 89.4% | 161% | – |
| Gross Profit | $39 | $37 | $19 | $8 |
| % Margin | 86.1% | 96.6% | 95.6% | 100% |
| EBITDA | -$58 | -$64 | -$84 | -$89 |
| % Margin | -125.8% | -168.6% | -417.9% | -1,163.6% |
| Net Income | -$61 | -$72 | -$85 | -$94 |
| % Margin | -132.4% | -189.3% | -423.3% | -1,226.2% |
| EPS Diluted | -0.7 | -0.83 | -0.99 | -1.1 |
| % Growth | 15.7% | 16.2% | 10% | – |
| Operating Cash Flow | -$71 | -$88 | -$95 | -$57 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$71 | -$88 | -$95 | -$57 |